Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.

NCT01705392 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT01705392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01705392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.
Lead sponsor
Haukeland University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2013
Completion date
February 20, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant melanoma, unresectable malignant melanoma